Multiple sclerosis: A pharmacotherapy update

Formulary

Volumn 32, Issue 5, 1997, Pages 472-499

  Tselis, Alex C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BACLOFEN; BETA1A INTERFERON; BETHANECHOL; CLADRIBINE; CLONAZEPAM; CORTICOTROPIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DANTROLENE; DIAZEPAM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHISOPRINOL; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PEMOLINE; PEMOLINE MAGNESIUM; PLACEBO; PREDNISONE; RECOMBINANT BETA INTERFERON; ROQUINIMEX; TIZANIDINE;

CHILL; CLINICAL TRIAL; DEPRESSION; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; MULTIPLE SCLEROSIS; MYALGIA; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; RELAPSE; REVIEW; SIDE EFFECT; SPASTICITY; THROMBOCYTOPENIA; VACCINATION;

EID: 0031007645     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Weinshenker BG, Rodriguez M. Epidemiology of multiple sclerosis. In: Gorelick PB, Alter M, eds. Handbook of Neuroepidemiology. New York: Marcel Dekker, 1994:chap 19.
2. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61.
3. Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-11.
4. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
5. Sadovnik AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
7. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
8. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
9. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
10. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 1996;46:12-18.
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
12. Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8.
13. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
14. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41:533-9.
15. Tourtellotte WW, Haerer AF. Use of an oral corticosteroid in the treatment of multiple sclerosis. Arch Neurol 1965; 12:536-45.
16. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
17. Silberberg DH. Azathioprine in multiple sclerosis. The cons. Neurology 1988;38 (Suppl 2):S24-S27.
18. Myers LW, Fahey JL, Moody DJ, et al. Cyclophosphamide "pulses" in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 1987;44:828-32.
19. Likosky WH. Experience with cyclophosphamide in multiple sclerosis: The cons. Neurology 1988;38(Suppl 2):S14-S18.
20. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-6.
21. Weiner HL, Mackin GA, Orav EJ, et al. Interminent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-8.
22. Milligan NM, Miller DH, Compston DAS. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57:164-8.
23. Currier RD, Haerer AF, Meydrech EF. Low-dose oral methotrexate treatment of multiple sclerosis: A pilot study. J Neurol Neurosurg Psychiatry 1993;56:1217-8.
24. Goodkin DE, Rudick RA, Medendorp SVB, et al. Low-dose (7.5 mg) methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
25. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.
26. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716-20.
27. Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: Preliminary study. Neurology 1980;30:1029-33.
28. Dau PC, Petajan JH, Johnson KP, et al. Plasmapheresis in multiple sclerosis: Preliminary findings. Neurology 1980;30:1023-28.
29. Tindall RSA, Walker JE, Ehle AL, et al. Plasmapheresis in multiple sclerosis: Prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 1982;32:739-43.
30. Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci 1985;12:39-44.
31. Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985;35:312-9.
32. Cook SD, Devereux C, Troiano R, et al. The treatment of patients with chronic progressive multiple sclerosis with total lymphoid irradiation. In: Cook SD, ed. Handbook of Multiple Sclerosis. New York: M Dekker, 1990:chap 18.
33. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo - the final report Neurology 1970;2(Suppl):1-159.
34. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations. Neurology 1986;36:238-43.
35. Milligan NM, Newcombe R, Compston DAS. Double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6.
36. Abbruzzese G, Gandolfo G, Loeb C. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci 1983;2:169-72.
37. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985;48:157-9.
38. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-71.
39. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-4.
40. Schapiro RT. Symptom management in multiple sclerosis. Ann Neurol 1994;36 (Suppl):123-9.
41. Smith CR, LaRocca NG, Giesser BS, Scheinberg LC. High-dose oral baclofen: Experience in patients with multiple sclerosis. Neurology 1991;41:1829-31.
42. Lazorthes Y, Sallerin-Caute B, Verdie JC, et al. Chronic intrathecal baclofen administration for the control of severe spasticity. J Neurosurg 1990;72:393-402.
43. Penn RD. Intrathecal baclofen for spasticity of spinal origin: Seven years of experience. J Neurosurg 1992;77:236-40.
44. Physicians' Desk Reference. Montvale, NJ: Medical Economics, 1994:1806-7.
45. Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticiry. Neurology 1994;44(Suppl 9):S21-S28.
46. Zanaflex (tizanidine HCl) package insert. Athena Neurosciences, Inc, South San Francisco, CA, December 1996.
47. Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. Neurology 1994;44(Suppl 9):S34-S43.
48. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44(Suppl 9):S70-S78.
49. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45:1956-61.
50. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: Progress from remyelination in the Theiler's virus model to a randomized, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994;57(Suppl):11-4.
51. Sorenson PS. Treatment of multiple sclerosis with IVIg: Potential effects and methodology of clinical trials. J Neurol Neurosurg Psychiatry 1994;57(Suppl):62-4.
52. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-24.
53. Weinshenker BG, Bass B, Karlik S, et al. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991;41:1047-52.
54. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. New Engl J Med 1990;323:1723-8.
55. Lindsey JW, Hodgkinson S, Mehta R, et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994;44:413-9.
56. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301.
57. Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein-autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis. Lancet 1995;346:807-8.
58. Karusis DM, Lehmann D, Slavin S, et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A 1993;90:6400-4.
59. Karusis DM, Lehmann D, Slavin S, et al. Immunomodulation of autoimmunity by linomide. Isr J Med Sci 1995;31:38-41.
60. Karusis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47:341-6.
61. Bever CT. Aminopyridines. In: Cook SD, ed. Handbook of Multiple Sclerosis. New York: Marcel Dekker, 1996:chap 17.
62. Claman HN, Tilles SA. Immunosuppressive and antiinflammatory actions of corticosteroids. In: Austen KF, Burakoff SJ, Rosen FS, Strom TB, eds. Therapeutic Immunology. Cambridge, MA: Blackwell Scientific, 1996:chap 8.
63. Knobler RL. Interferon beta-1b treatment of multiple sclerosis. In: Reder AT, ed. Interferon Therapy of Multiple Sclerosis. New York: Marcel Dekker, 1997:chap 14.
64. Johnson KP. Interferon therapy of multiple sclerosis. In: Cook SD, ed. Handbook of Multiple Sclerosis. New York: Marcel Dekker, 1996:chap 14.
65. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994;44:1537-40.